Form 8-K - Current report:
SEC Accession No. 0001140361-25-018800
Filing Date
2025-05-14
Accepted
2025-05-14 07:35:17
Documents
15
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20048917_8k.htm   iXBRL 8-K 28024
2 EXHIBIT 99.1 ef20048917_ex99-1.htm EX-99.1 86226
6 image00001.jpg GRAPHIC 3419
  Complete submission text file 0001140361-25-018800.txt   264936

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pdsb-20250514.xsd EX-101.SCH 3988
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pdsb-20250514_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pdsb-20250514_pre.xml EX-101.PRE 16048
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20048917_8k_htm.xml XML 4076
Mailing Address 303A COLLEGE ROAD EAST PRINCETON NJ 08540
Business Address 303A COLLEGE ROAD EAST PRINCETON NJ 08540 800-208-3343
PDS Biotechnology Corp (Filer) CIK: 0001472091 (see all company filings)

EIN.: 264231384 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37568 | Film No.: 25942663
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)